Author(s): Safeena Beevi S S, Biju Pottakkat, Sankar Narayanan

Email(s): bijupottakkat@gmail.com

DOI: 10.52711/2349-2996.2023.00034   

Address: Safeena Beevi S S1, Biju Pottakkat2*, Sankar Narayanan2
1Associate Professor, College of Nursing, JNMC, Aligarh Muslim University, Uttar Pradesh, India.
2Professor, Department of Surgical Gastroenterology, JIPMER, Puducherry, India.
2Consultant, Department of Surgical Gastroenterology, Billroth Hospitals, Chennai, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 2,     Year - 2023


ABSTRACT:
The complex combination of numerous microbes present in the GI tract of human being is referred to as Gut microbiota, consists of almost 1000 microbial cells, that is almost many times higher than that of human tissues in a person. The intestinal microbiota in each person has a completely unique blend of species. Trillions of microbes are present in the human body which include both beneficial and dangerous organisms. The microbiota plays a crucial role in nutritional status, immune level and effects on the behaviour and cognitive development. The human gastrointestinal tract has many bacterial species, provides a microbial barrier in opposition to potential pathogens and it regulates the frame's immune responses. The gut microbiota composition has a major function in the occurrence of liver illnesses. Variations within the gut microbiota seem to have an important position in the pathogenesis and progression of many gastrointestinal and liver sicknesses. Alterations within the features of liver-intestine axis can cause release of pro-inflammatory cytokines and autoimmune responses inside the liver which can have deleterious impact on liver cells. Administration of health enhancing microbes may ameliorate dangerous interactions and hepatic disorders. This review addresses the role of intestine microbiota in hepatic diseases and the impact of probiotics in the management of hepatic diseases.


Cite this article:
Safeena Beevi S S, Biju Pottakkat, Sankar Narayanan. Role of Probiotics and Gut microbiota in Liver Diseases. Asian Journal of Nursing Education and Research. 2023; 13(2):157-1. doi: 10.52711/2349-2996.2023.00034

Cite(Electronic):
Safeena Beevi S S, Biju Pottakkat, Sankar Narayanan. Role of Probiotics and Gut microbiota in Liver Diseases. Asian Journal of Nursing Education and Research. 2023; 13(2):157-1. doi: 10.52711/2349-2996.2023.00034   Available on: https://ajner.com/AbstractView.aspx?PID=2023-13-2-17


REFERENCES:
1.    FAO/WHO, Guidelines for the evaluation of probiotics in food 2006.
2.    Experimental Biology 2018. "Growing evidence that probiotics are good for your liver: In mice, probiotic treatment shown to protect against liver damage from acetaminophen." Science Daily. 23 April 2018. <www.sciencedaily.com/releases/2018/04/180423085445.htm>.
3.    Backhed F. Programming of host metabolism by the gut microbiota. Ann NutrMetab 2011: 58: 44-52.
4.    Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis; pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-39
5.    Nitin J, Mithun S, Rao PN, Nageshwar Reddy D. Liver Diseases: The Role of Gut Microbiota and Probiotics. J Prob Health 2016; 4: 154-62. doi: 10.4172/2329-8901.1000154.
6.    Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulationand neuromodulation. Ther Adv Gastroenterol 2013; 6(1): 39–51.
7.    De Palma G, Lynch MDJ, Lu J, Dang VT, Deng Y, Jury J, Umeh G, Miranda PM, Pigrau Pastor M, Sidani S, Pinto-Sanchez MI, Philip V, McLean PG, Hagelsieb M-G, Surette MG, Bergonzelli GE, Verdu EF, Britz-McKibbin P, Neufeld JD, Collins SM, Bercik P. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. SciTransl Med. 2017;9 (379): eaaf6397. doi: 10.1126/scitranslmed.aaf6397.
8.    Wiley NC, Dinan TG, Ross RP, Stanton C, Clarke G, Cryan JF. The microbiota-gut-brain axis as a key regulator of neural function and the stress response: implications for human and animal health. Journal of Animal Science. 2017; 95:3225- 46.
9.    Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, Abe F, Osawa R. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study.BMC Microbiol. 2016; 16(1):90.
10.    Nagpal R, Tsuji H, Takahashi T, Nomoto K, Kawashima K, Nagata S, Yamashiro Y. Front Microbiol. Ontogenesis of the Gut Microbiota Composition in Healthy, Full-Term, Vaginally Born and Breast-Fed Infants over the First 3 Years of Life: A Quantitative Bird's-Eye View. 2017; 8(4):1388.
11.    Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, Beaumont M, Van Treuren W, Knight R, Bell JT, Spector TD, Clark AG, Ley RE. Human genetics shape the gut microbiome. Cell. 2014;159(4):789-99.
12.    Amit Goel, Mahesh Gupta and Rakesh Aggarwal. Gut microbiota and liver disease. Journal of Gastroenterology and Hepatology 29 (2014) 1139–48.
13.    Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. NeurogastroenterolMotil. 2012 Jun;24(6):503-12.
14.    Hsin-Jung Wu, Eric Wu. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012; 3(1): 4-14.
15.    Yiu JH, Dorweiler B, Woo CW. Interaction between gut microbiota and toll-like receptor: from immunity to metabolism. J Mol Med (Berl). 2017 Jan;95(1):13-20. doi: 10.1007/s00109-016-1474-4.
16.    www.worldlifeexpectancy.com. WHO 2018 report on liver diseases.
17.    Meng X, Li S, Li Ya, Gan RY, Li HB. Gut Microbiota’s Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics. Nutrients 2018, 10(10), 1457.
18.    Sharma V, Garg S, Aggarwal S. Probiotics and Liver Disease. Perm J 2013 Fall;17(4):62-67.
19.    Panesar PS, Kumari S. Lactulose: production, purification and potential applications. Biotechnol Adv 2011 Nov-Dec; 29(6):940-8.
20.    Gibson GR, Scott KP, Rastall RA, Tuohy KM, Hotchkiss AT, Ferrandon AB, Gareau MG. Detary prebiotics: current status and new definition. Food Sci Technol Bull: Funct foods. 2010; 7:1-19. 7(1):1-19. 10.1616/1476-2137.15880.
21.    Sekita, A.; Okazaki, Y.; Katayama, T. Dietary phytic acid prevents fatty liver by reducing expression ofhepatic lipogenic enzymes and modulates gut microflora in rats fed a high-sucrose diet. Nutrition 2016, 32, 720–722.
22.    Song, H.; Chu, Q.; Yan, F.; Yang, Y.; Han, W.; Zheng, X. Red pitaya betacyanins protects from diet-inducedobesity, liver steatosis and insulin resistance in association with modulation of gut microbiota in mice.J. Gastroenterol. Hepatol. 2016, 31, 1462–69.
23.    Feng, Q.; Liu, W.; Baker, S.S.; Li, H.; Chen, C.; Liu, Q.; Tang, S.; Guan, L.; Tsompana, M.; Kozielski, R.; et al. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment ofnon-alcoholic fatty liver disease. Oncotarget 2017, 8, 27820–38.
24.    Zhang, X.; Wang, H.; Yin, P.; Fan, H.; Sun, L.; Liu, Y. Flaxseed oil ameliorates alcoholic liver disease viaanti-inflammation and modulating gut microbiota in mice. Lipids Health Dis. 2017, 16, 44.
25.    Zhao C, Yang C, Chen M, Lv X, Liu B, Yi L, Cornara L, Wei MC, Yang YC, Tundis R, Xiao J. Regulatory efficacy of brown seaweed Lessonia nigrescens extract on the gene expression profile and intestinalmicroflora in type 2 diabetic mice. Mol Nutr Food Res. 2018 Feb;62 (4). doi: 10.1002/mnfr.201700730. Epub 2018 Jan 12.
26.    Rishi, P.; Arora, S.; Kaur, U.J.; Chopra, K.; Kaur, I.P. Better management of alcohol liver disease usinga ‘MicrostructuredSynbox’ System comprising L. plantarum and EGCG. PLoS One 2017, 12, e0168459
27.    Arora, S.; Kaur, I.P.; Chopra, K.; Rishi, P. Efficiency of double layered microencapsulated probiotic tomodulate proinflammatory molecular markers for the management of alcoholic liver disease. Mediat. Inflamm.2014, 2014, 715130
28.    Duseja A. Non alcoholic fatty liver disease in India- a lot done, yet more required. Indian J gastroenterol. 2010; 29(6): 217-25
29.    Xin, J.; Zeng, D.; Wang, H.; Ni, X.; Yi, D.; Pan, K.; Jing, B. Preventing non-alcoholic fatty liver diseasethrough Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improvinggut environment in obese mice. Appl. Microbiol. Biotechnol. 2014, 98, 6817–29.
30.    Xie C, De Marizio DH. Role of probiotics in non – alcoholic fatty liver disease: Does gut microbiota Matter? Nutrients. 2019;11(11):2837.
31.    Asgharian A., Askari G., Esmailzade A., Feizi A., Mohammadi V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int. J. Prev. Med. 2016;7:59. doi: 10.4103/2008-7802.178533.
32.    Ferolla S.M., Couto C.A., Costa-Silva L., Armiliato G.N., Pereira C.A., Martins F.S., Ferrari Mde L., Vilela E.G., Torres H.O., Cunha A.S., et al. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients. 2016;8:397. doi: 10.3390/nu8070397.
33.    Sepideh A., Karim P., Hossein A., Leila R., Hamdollah M., Mohammad E.G., Mojtaba S., Mohammad S., Ghader G., Seyed Moayed A. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. J. Am. Coll Nutr. 2016;35:500–505. doi: 10.1080/07315724.2015.1031355.
34.    Abdel Monem S.M. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J. Hepatogastroenterol. 2017;7:101–106. doi: 10.5005/jp-journals-10018-1226.
35.    Behrouz V., Jazayeri S., Aryaeian N., Zahedi M.J., Hosseini F. Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Middle East. J. Dig. Dis. 2017;9:150–157. doi: 10.15171/mejdd.2017.66.
36.    Ekhlasi G., Zarrati M., Agah S., Hosseini A.F., Hosseini S., Shidfar S., SoltaniAarbshahi S.S., Razmpoosh E., Shidfar F. Effects of synbiotics and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease. EXCLI J. 2017;16:278–290. doi: 10.17179/excli2016-846
37.    Famouri F., Shariat Z., Hashemipour M., Keikha M., Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J. Pediatr. Gastroenterol. Nutr. 2017;64:413–417. doi: 10.1097/MPG.0000000000001422.
38.    Manzhalii E., Virchenko O., Falalyeyeva T., Beregova T., Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. J. Dig. Dis. 2017;18:698–703. doi: 10.1111/1751-2980.12561.
39.    Mofidi F., Poustchi H., Yari Z., Nourinayyer B., Merat S., Sharafkhah M., Malekzadeh R., Hekmatdoost A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial. Br. J. Nutr. 2017;117:662–668. doi: 10.1017/S0007114517000204.
40.    Bakhshimoghaddam F., Shateri K., Sina M., Hashemian M., Alizadeh M. Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. J. Nutr. 2018;148:1276–1284. doi: 10.1093/jn/nxy088.
41.    Javadi L., Khoshbaten M., Safaiyan A., Ghavami M., Abbasi M.M., Gargari B.P. Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease. Asia Pac. J. Clin. Nutr. 2018;27:1031–1039. doi: 10.6133/apjcn.042018.05.
42.    Kobyliak N., Abenavoli L., Falalyeyeva T., Mykhalchyshyn G., Boccuto L., Kononenko L., Kyriienko D., Komisarenko I., Dynnyk O. Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: A randomized clinical study. Minerva Med. 2018;109:418–428. doi: 10.23736/S0026-4806.18.05845-7.
43.    Kobyliak N., Abenavoli L., Mykhalchyshyn G., Kononenko L., Boccuto L., Kyriienko D., Dynnyk O. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial. J. Gastrointestin. Liver Dis. 2018;27:41–49. doi: 10.15403/jgld.2014.1121.271.kby.
44.    Sayari S., Neishaboori H., Jameshorani M. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2018;24:331–338. doi: 10.3350/cmh.2018.0006.
45.    Wang W., Shi L.P., Shi L., Xu L. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease. ZhonghuaNeiKe Za Zhi. 2018;57:101–106. doi: 10.3760/cma.j.issn.0578-1426.2018.02.004.
46.    Ahn S.B., Jun D.W., Kang B.K., Lim J.H., Lim S., Chung M.J. Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci. Rep. 2019;9:5688. doi: 10.1038/s41598-019-42059-3.
47.    Xiao MW, Lin XS, Hua Shen Z, Luo WW, Yan Wang X. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gateroenterology Research and practice. 2019 |Article ID 1484598 | https://doi.org/10.1155/2019/1484598
48.    Liu Y, Jin Y, Li J, Zhao L, Li Z, Xu J, Zhao F, Feng J, Chen H, Fang C, Shilpakar R, Wei Y. Small bowel transit and altered gut microbiota in patients with liver cirrhosis. Front Physiol. 2018 May 1;9:470. doi: 10.3389/fphys.2018.00470. PMID: 29780327.
49.    Newaz Hossain, Pushpjeet Kanwar, and Smruti R. Mohanty. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gateroenterology Research and practice. 2016 |Article ID 7109270 | https://doi.org/10.1155/2016/7109270
50.    Li, M.; Zhu, L.; Xie, A.; Yuan, J. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 2015, 38, 170–179.
51.    Murphy LY, Wan Hani El-Nezami. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary SurgNutr. 2018 Feb; 7(1): 11–20.
52.    Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F, Sanguinetti M, Morelli D, ParoniSterbini F, Petito V, Reddel S, Calvani R, Camisaschi C, Picca A, Tuccitto A, Gasbarrini A, PompiliM, Mazzaferro V. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019 Jan;69(1):107-120. doi: 10.1002/hep.30036. Epub 2018 Jul 10. PMID: 29665135.
53.    Sarika Lokhande, Savita More, Vijay Raje. A Systematic Study of Probiotics- An Update Review. Asian J. Pharm. Tech. 2018; 8 (3):149-157 . doi: 10.5958/2231-5713.2018.00024.7
54.    Md Kamal Hossain, Kamrun Nahar, Parisa Shokryazdan, Norhani Abdullah, Kaiser Hamid, Mohammed FaselehJahromi. Probiotic Potential of Lactic Acid Bacteria Isolated from Cheese, Yogurt and Poultry Faeces. Research J. Pharm. and Tech. 2017; 10(9): 2991-2998. doi: 10.5958/0974-360X.2017.00530.3
55.    Nimmy Abraham, Chitra Namachivayam, Sangeetha Sundaramoorthy. Lactobacillus- An friendly Bacteria. International Journal of Technology. 2021; 11(2):70-7. doi: 10.52711/2231-3915.2021.00010
56.    K.V. Swathi. Probiotics –A Human Friendly Bacteria. Research J. Pharm. and Tech 2016; 9(8):1260-1262. doi: 10.5958/0974-360X.2016.00239.0
57.    Wissam Zam, Reine Dawod. Overview of the Probiotics’ role in Gastrointestinal disorders. Research J. Pharm. and Tech. 2020; 13(11):5557-5561. doi: 10.5958/0974-360X.2020.00970.1

Recomonded Articles:

Author(s): Vinil Upendrababu, Sweta, Ujjwal P. Lorenz, Upma Vimal, Veena Sharma, Vimla Kushwaha, Vivek Kumar

DOI: 10.5958/2349-2996.2018.00093.9         Access: Open Access Read More

Author(s): Ramya K.R, Vineetha R.

DOI:         Access: Open Access Read More

Author(s): Nithya Sara James, Princy S, Priya Samson, Reshma Sara Shaji, Shilpa S, Sheeja S

DOI: 10.52711/2349-2996.2022.00024         Access: Open Access Read More

Author(s): Rishi Dutt Avasthi

DOI: 10.5958/2349-2996.2017.00117         Access: Open Access Read More

Author(s): Amandeep Kaur, Rehana Ahad, Minakshi Modgill, Mitushi Masih, Navjit Kaur, Navjot Kaur, Parampreet Kaur, Paramveer Kaur, Parveen Kaur Handa, Poonam Sharma, Prabhdeep Kaur, Prabhjot Kaur, Rajdeep Kaur, Rajni

DOI: 10.5958/2349-2996.2019.00046.6         Access: Open Access Read More

Author(s): Sachdeva Seema, Koul Pity, Batra Kiran

DOI: 10.5958/2349-2996.2017.00115.X         Access: Open Access Read More

Author(s): Anitha Victoria Noronha, Sheela Williams, Rakesh A N, Shashikumar H N

DOI: 10.5958/2349-2996.2017.00042.8         Access: Open Access Read More

Asian Journal of Nursing Education and Research (AJNER) is an international, peer-reviewed journal devoted to nursing sciences....... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2349-2996 

Popular Articles


Recent Articles




Tags